1. Home
  2. PFLT vs CTMX Comparison

PFLT vs CTMX Comparison

Compare PFLT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Floating Rate Capital Ltd.

PFLT

PennantPark Floating Rate Capital Ltd.

HOLD

Current Price

$7.46

Market Cap

742.1M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.75

Market Cap

716.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFLT
CTMX
Founded
2010
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
742.1M
716.9M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
PFLT
CTMX
Price
$7.46
$3.75
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$10.50
$12.10
AVG Volume (30 Days)
878.5K
2.7M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
14.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
$8.16
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
$24.14
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$6.83
$1.90
52 Week High
$10.29
$8.21

Technical Indicators

Market Signals
Indicator
PFLT
CTMX
Relative Strength Index (RSI) 54.57 61.85
Support Level $7.03 $3.66
Resistance Level $7.67 $3.96
Average True Range (ATR) 0.12 0.19
MACD 0.01 0.04
Stochastic Oscillator 78.69 80.42

Price Performance

Historical Comparison
PFLT
CTMX

About PFLT PennantPark Floating Rate Capital Ltd.

PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: